

Childhood Adversity and Schizophrenia:

The Protective Role of Resilience in Mental and Physical Health and Metabolic Markers

Ellen E. Lee, MD^{a,b}; Averria Sirkin Martin, PhD^{a,b}; Xin Tu, PhD^{a,c}; Barton W. Palmer, PhD^{a,d}; and Dilip V. Jeste, MD^{a,b,e,*}

ABSTRACT

Objective: To determine the impact of childhood adversity and current (adulthood) resilience on mental and physical health and markers of metabolic function among adults with schizophrenia and nonpsychiatric comparison participants (NCs).

Methods: We conducted a cross-sectional study of 114 participants with schizophrenia (*DSM-IV-TR* criteria) and 101 NCs aged 26–65 years during 2012–2017. Sociodemographic, clinical, and laboratory measures were examined. Childhood Trauma Questionnaire was used to retrospectively assess emotional abuse/neglect, physical abuse/neglect, and sexual abuse experienced during childhood. Connor-Davidson Resilience Scale was employed to measure resilience.

Results: Persons with schizophrenia reported more severe childhood trauma, lower resilience, and worse mental and physical health and had worse metabolic biomarker levels than NCs. Trauma severity correlated with worse depression in the NCs ($r = 0.34$), but not in the schizophrenia group ($r = 0.02$). In both groups, trauma severity was associated with worse physical well-being, higher fasting insulin levels, and greater insulin resistance ($P \leq .02$). Notably, resilience appeared to counteract effects of trauma and diagnosis on mental and physical health. The schizophrenia subgroup with high resilience and severe trauma reported mental and physical well-being and had glycosylated hemoglobin levels and insulin resistance scores that were comparable to those of NCs with low resilience and severe trauma.

Conclusions: To our knowledge, this is the first study to quantitatively assess effects of both childhood trauma and resilience in schizophrenia on health, notably metabolic function. Interventions to bolster resilience in the general population and in people with schizophrenia may improve outcomes for those with a history of childhood adversity.

J Clin Psychiatry 2018;79(3):17m11776

To cite: Lee EE, Martin AS, Tu X, et al. Childhood adversity and schizophrenia: the protective role of resilience in mental and physical health and metabolic markers. *J Clin Psychiatry*. 2018;79(3):17m11776.

To share: <https://doi.org/10.4088/JCP.17m11776>
© Copyright 2018 Physicians Postgraduate Press, Inc.

^aDepartment of Psychiatry, University of California San Diego, La Jolla, California

^bSam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, California

^cDepartment of Family Medicine and Public Health, University of California San Diego, La Jolla, California

^dVeterans Affairs San Diego Healthcare System, San Diego, California

^eDepartment of Neurosciences, University of California, San Diego, California

*Corresponding author: Dilip V. Jeste, MD, University of California San Diego, 9500 Gilman Dr, #0664, La Jolla, CA 92093 (djeste@ucsd.edu).

Childhood maltreatment has been linked to worse mental and physical health and premature mortality in the general population.^{1–4} Afifi et al⁵ reported that all types of childhood abuse were associated with physical illnesses, increased risk of obesity, and worse self-reported physical health in a nationwide Canadian study. Even when sociodemographic variables, smoking, and obesity were accounted for, abuse was associated with a variety of physical illnesses including arthritis, cancer, stroke, and back problems.

Several meta-analyses have shown that schizophrenia, a debilitating mental illness with prominent psychotic and negative symptoms, is strongly associated with childhood adversity, with a 2- to 7-fold higher prevalence of childhood abuse than in nonpsychiatric comparison participants (NCs).^{6–8} While there is no demonstrated causal link between trauma and psychosis,⁸ childhood abuse appears to be associated with transition to psychosis⁹ and is more prevalent among persons with psychotic disorders compared to those with mood or anxiety disorders.¹⁰ Studies in people with schizophrenia and other serious mental illnesses consistently report that a history of childhood abuse is associated with poor outcomes, including worse psychopathology,¹¹ worse social functioning,¹² treatment resistance,¹³ and lower quality of life.¹⁴ More specifically, childhood abuse is associated with positive symptoms,^{11,15} while childhood neglect is associated with negative symptoms.¹⁵

Schizophrenia is also associated with increased physical morbidity and premature mortality, attributable to increased cardiovascular-related mortality, although the exact biological mechanisms are not clear.^{16,17} Metabolic dysfunction, a major risk factor for cardiovascular-related death, is more common in individuals with schizophrenia than in the general population; this is related in part to higher rates of smoking, sedentary behaviors, unhealthy diet, obesity, and long-term treatment with antipsychotic medications.^{16,18,19} However, dysregulated glucose homeostasis,²⁰ an important component of metabolic dysfunction, has been observed even in antipsychotic-naïve, normal-weight, first-episode patients²¹ and is more prevalent in individuals at elevated risk for schizophrenia.¹⁹ This literature suggests that while obesity and antipsychotic medications may contribute to metabolic dysfunction in persons with schizophrenia, there may be other contributing factors that are intrinsic to having schizophrenia and that precede the cumulative metabolic burden of lifestyle behaviors.²²

Childhood trauma itself may contribute to metabolic dysfunction in schizophrenia. One study in stable outpatients with schizophrenia ($N = 62$) found that overweight or obese participants had higher subscale scores of emotional abuse, emotional neglect, and physical neglect and higher total Childhood Trauma Questionnaire (CTQ) scores.²³ Similarly, one study in nonobese first-episode schizophrenia participants with minimal antipsychotic exposure

- Both childhood adversity and psychological resilience affect mental and physical health, yet this relationship has not been studied in persons with schizophrenia.
- Persons with schizophrenia who have high levels of resilience and severe trauma have comparable or better mental and physical health as nonpsychiatric comparison subjects with low levels of resilience and severe trauma.
- Resilience may counter the negative effects of childhood adversity on mental and physical health in both persons with schizophrenia and the general population.

($N = 83$) found that those with a history of childhood trauma ($n = 33$) had higher LDL cholesterol levels.²⁴ Another study in first-episode psychosis patients ($n = 28$) and NCs ($n = 45$) reported that patients with childhood maltreatment had higher body mass index (BMI) than NCs.²⁵ It has been reported that childhood adversity leads to neuroendocrine dysregulation and chronic inflammation, resulting in metabolic, endocrine, and immune pathology.²⁶

In contrast to the negative effects of trauma, resilience may positively impact health.²⁷ Psychological resilience is a moderately heritable (30%–50%) and relatively stable trait^{28–31} characterized by “positive adaptation, or the ability to maintain or regain mental health, despite experiencing adversity.”^{30(p259)} In physically ill patients and the general population, resilience is associated with medically desirable behaviors (eg, adherence to self-care routines, psychiatric treatment, and exercise) and better health outcomes (eg, better emotional health, less depression, less pain, better social functioning, less alcohol and illicit substance use, and better physical health).^{32–37} In fact, resilience may even impact longevity. In a community-dwelling population 65 years or older, higher resilience was associated with 35.3% lower mortality risk.³⁸ Of these studies, 1³² used the 25-item Connor-Davidson Resilience Scale (CDRS), 3^{34–36} used the 10-item CDRS, and 1³⁸ chose 7 culturally relevant items from the CDRS. The others used the Resilience Scale^{39,40} or a proxy of resilience based on factors such as self-efficacy, self-esteem, self-mastery, and optimism.^{33,37} Despite differences between these measures of resilience, all studies showed how psychological resilience improved mental health, physical health, and mortality. Although resilience may have a moderating effect on the deleterious impact of childhood trauma on health in people in schizophrenia, to our knowledge there have been no prior published studies examining that possibility. In the present study, we focus specifically on the role of resilience in tempering the effects of childhood adversity on mental health outcomes (eg, mental well-being and perceived stress) and physical health outcomes (eg, physical well-being, medical comorbidity, BMI, and metabolic biomarkers).

In this investigation of persons with schizophrenia and NCs, the relationships between sociodemographic, psychopathological, and mental and physical health variables, as well as metabolic biomarkers, were analyzed to assess the association of childhood adversity with subsequent

(adulthood) mental and physical health outcomes. Based on the findings of high prevalence of childhood adversity in persons with psychotic disorders, we hypothesized that persons with schizophrenia would have histories of worse childhood adversity than demographically comparable NCs. Additionally, given the association between childhood trauma and worse psychopathology, worse social functioning, and obesity, we hypothesized that greater childhood adversity would be associated with worse mental and physical health as well as worse levels of metabolic biomarkers among people with schizophrenia and NCs and with worse psychopathology in the persons with schizophrenia. Lastly, in light of the link observed between resilience and better health behaviors and longevity, we hypothesized that resilience would neutralize the impact of childhood adversity on mental and physical health, including metabolic biomarkers in both subject groups.

METHODS

Study Participants

Participants included 114 persons with schizophrenia and 101 NCs. Data for the present report were collected between 2012–2017 as part of a larger ongoing study of aging in schizophrenia. Details of the parent protocol and recruitment are available in Joseph et al.⁴¹ Briefly, noninstitutionalized persons with *DSM-IV-TR* diagnoses of schizophrenia or schizoaffective disorder and NCs aged 26 to 65 years were recruited from the greater San Diego area. Most participants have provided data to prior published reports,^{41–45} and data on resilience on a subset of these participants have been presented previously⁴⁶; however, this is our first examination of childhood trauma in these participants.

The Structured Clinical Interview for *DSM-IV-TR* (SCID) was used to determine schizophrenia or schizoaffective disorder diagnosis.⁴⁷ The Mini-International Neuropsychiatric Interview (MINI)⁴⁸ was used to screen NCs, who were excluded if they were found to have a past or present diagnosis of a major neuropsychiatric illness. Other exclusion criteria were (1) other current *DSM-IV-TR* Axis I diagnoses; (2) alcohol or other non-tobacco substance abuse or dependence within 3 prior months; (3) diagnosis of dementia, intellectual disability disorder, or a major neurologic disorder; and (4) medical disorder affecting a subject's ability to complete study procedures. The subjects were recruited in age-bins to yield comparable numbers across the full age range, and recruitment of NCs was stratified by gender, relative to the schizophrenia group, to yield comparable proportions of men and women within each study group. The study protocol was approved by the UC San Diego Human Research Protections Program, and each participant provided written informed consent prior to participation.

Sociodemographic Characteristics and Psychopathology

Trained study staff interviewed the participants and administered standardized assessments for psychotic

It is illegal to post this copyrighted PDF on any website.

symptoms (Scales for the Assessment of Positive and Negative Symptoms^{49,50}), depression (Calgary Depression Rating Scale⁵¹), and anxiety (Brief Symptom Inventory Anxiety Scale⁵²).

Mental Health Measures

Resilience was determined with the 10-item self-report CDRS, which evaluated hardiness (“ability to cope with change and adversity”) and persistence (“putting forth one’s best effort despite adverse circumstances”).^{53,54} The 10-item CDRS was derived from the original 25-item scale and has been found to have good reliability (Cronbach $\alpha = 0.85$). Each item response is scored on a 5-point Likert scale ranging from not true at all, rarely true, sometimes true, often true, and true nearly all of the time. Two such items include “I believe I can achieve my goals, even if there are obstacles” and “Under pressure, I stay focused and think clearly.” Individuals report how they have felt over the past month. Total scores range from 0 to 40, with higher scores reflecting greater resilience.

Other mental health variables included mental well-being (Short Form Health Survey—Mental)⁵⁵ and perceived stress (Perceived Stress Scale).⁵⁶ While resilience (as measured by CDRS) is a stable trait of hardiness/persistence, mental well-being (as measured by Short Form Health Survey—Mental) is an outcome state that can fluctuate. The scales have no overlapping items. Cognitive measures included overall severity of cognitive deficits (Modified Telephone Interview for Cognitive Status^{57,58}) and an executive functioning composite score (derived from selected subtests from the Delis-Kaplan Executive Function System⁵⁹).

Physical Health Measures

Physical health variables included physical well-being (Short Form Health Survey—Physical) and medical comorbidity (Cumulative Illness Rating Scale).^{55,60} Height and weight were measured using a standard scale and wall-affixed height scale. BMI was calculated from the subject’s height and weight.

Childhood Trauma Assessment

Study participants completed the CTQ, a 25-item scale composed of 5 subscales that retrospectively assess emotional abuse, emotional neglect, physical abuse, physical neglect, and sexual abuse.⁶¹ The CTQ has high internal consistency (Cronbach $\alpha = 0.79$ – 0.94) and good test-retest reliability over 2–6 month interval (intraclass correlation = 0.88). The CTQ has been used in a number of published studies^{10,62,63} and has specified cut-off classifications to describe severity of trauma in each of the 5 subscales.^{61,62}

Each CTQ subscale has 4 severity classifications (None/Minimal, Low/Moderate, Moderate/Severe, Severe/Extreme). On the basis of these classifications, the severe trauma group was defined as having 1 or more CTQ subscale severity that was classified as Moderate/Severe or Severe/Extreme, while the low trauma group was defined

as having all CTQ subscales rated as either None/Minimal or Low/Moderate in severity.

Biomarker Assays

All assays were processed from a baseline fasting blood draw of roughly 65 mL of blood.

Fasting serum insulin levels were processed at the UC San Diego Core laboratory using serum samples that were frozen at -80°C and assayed using standard methods in duplicate (Quantitative Chemiluminescent Immunoassay). Fasting blood glucose and glycosylated hemoglobin assays were completed at the UC San Diego Hospital laboratory using standard laboratory assays. Glycosylated hemoglobin assays are a stable measure of insulin resistance, reflecting glucose homeostasis over the past 120 days.

Homeostatic model assessment of insulin resistance (HOMA-IR) values were calculated from the fasting plasma insulin and fasting plasma glucose measures using the following formula⁶⁴:

$$\text{HOMA-IR} = [\text{fasting plasma insulin (mIU/L)} \times \text{fasting plasma glucose (mmol/L)}] / 22.5.$$

Statistical Analyses

Variables were assessed for violation of distribution assumptions for inferential statistics and were log-transformed as necessary. Significance of differences between schizophrenia and NC groups was assessed with independent-sample t tests for continuous variables and Pearson χ^2 for categorical variables. The association of total CTQ score with measures of psychopathological variables, mental and physical health variables, and metabolic biomarkers was assessed within each diagnostic group using Spearman ρ . The null of common Spearman correlation between the schizophrenia and NC groups was tested by comparing 2 independent Spearman correlations.

General linear models were used to analyze the effects of trauma severity, subject group, and resilience on mental and physical health measures and metabolic biomarker levels. We limited the analyses to the outcome variables that were highlighted in the literature (mental well-being, physical well-being, BMI, glycosylated hemoglobin, and HOMA-IR). Model 1 included subject group (NC vs schizophrenia), trauma severity (CTQ total score), and group \times trauma severity interaction. Model 2 included subject group (NC vs schizophrenia), trauma severity (CTQ total score), resilience (CDRS score), group \times trauma severity interaction, and group \times resilience interaction. We also ran 2 additional models: model 3 included the subject group, trauma, resilience, group \times trauma, group \times resilience, and trauma \times resilience interactions; model 4 included subject group, trauma, resilience, group \times trauma, group \times resilience, trauma \times resilience, and group \times trauma \times resilience interactions. The additional interactions in models 3 and 4 were not significant, so these interactions were not reported in the table. We used linear contrast tests and post hoc independent-samples t tests to compare multiple mental and

Table 1. Clinical Characteristics of the Schizophrenia and Healthy Comparison Groups

	Nonpsychiatric Participants			Schizophrenia Group			<i>t</i> or χ^2	<i>df</i>	<i>P</i> Value (2-Tailed)	Cohen <i>d</i>
	<i>n</i>	Value ^a	SD	<i>n</i>	Value ^a	SD				
Demographic factors										
Age at visit, <i>y</i>	101	49.4	11.3	114	48.3	10.1	0.74		.5	0.1
Gender, ^b % female		53.4			43.9		1.98	1	.2	
Race, ^b % Caucasian		60.3			50.0		2.34	1	.1	
Education, <i>y</i>	101	14.7	2.2	114	12.5	2.4	7.03	213	<.001	0.96
Psychopathology										
Duration of illness, <i>y</i>				111	25.4	10.9				
Antipsychotic dose, mg ^c				114	1.91	1.59				
Positive symptoms ^d				114	6.02	4.23				
Negative symptoms ^e				114	7.00	4.33				
Depressive symptoms ^f	100	0.54	1.25	114	3.54	3.92	-7.72	138.6	<.001	-1.03
Anxiety symptoms ^g	92	1.3	2.1	111	7.2	6.4	-9.23	138.2	<.001	-1.25
Mental health										
Resilience ^h	92	33.1	5.7	110	23.4	8.2	9.95	193.6	<.001	1.38
Mental well-being ⁱ	92	54.6	6.1	111	43.2	11.3	9.12	175.3	<.001	1.25
Perceived stress ^j	91	10.6	6.14	111	18.5	6.41	-8.85	200	<.001	-1.25
Overall cognitive dysfunction ^k	99	38.0	4.1	111	31.5	5.6	9.74	199.4	<.001	1.33
Executive functioning ^l	101	0.42	0.55	114	-0.46	0.72	10.2	208.2	<.001	1.38
Physical health										
Physical well-being ^m	92	51.7	9.5	111	43.6	10.2	5.87	198.6	<.001	0.83
Physical comorbidity ⁿ	101	2.83	3.12	114	6.40	4.32	-7	205	<.001	-0.95
BMI	101	27	6.2	112	32.3	7.4	-5.7	210	<.001	-0.78
Metabolic biomarkers										
Fasting insulin, mIU/L	96	6.97	5.61	106	13.03	11.98	-4.71	196.5	<.001	-0.66
Fasting glucose, mg/dL	101	89.5	17.0	113	105.5	50.9	-2.97	165	.003	-0.4
Hemoglobin A _{1c} , %	87	5.7	0.63	95	6.1	1.25	-2.54	152.6	.012	-0.37
HOMA-IR	96	1.6	1.53	106	3.8	5.13	-5.23	194.4	<.001	-0.73
Childhood adversity measures ^o										
Emotional Abuse subscale score	101	8.31	3.94	114	10.66	4.81	-3.89	213	<.001	-0.53
Physical Abuse subscale score	101	7.00	3.04	114	8.81	4.55	-3.46	198.4	.001	-0.47
Sexual Abuse subscale score	99	6.71	3.86	114	9.10	5.81	-3.58	198	<.001	-0.48
Emotional Neglect subscale score	101	9.48	4.64	114	12.03	4.78	-3.96	213	<.001	-0.54
Physical Neglect subscale score	101	6.77	2.98	114	9.08	3.47	-5.24	212.8	<.001	-0.71
Total score	99	38.3	14.0	114	49.7	17.1	-5.27	211	<.001	-0.73

^aMean values unless otherwise noted.^b χ^2 test.^cAntipsychotic medication daily dosages were converted to WHO average daily doses based on published standards (WHO Guidelines for ATC Classification and DDD Assignment⁶⁶ and WHO Introduction to Drug Utilization Research, 2009⁶⁷).^dAs assessed with the Scale for the Assessment of Positive Symptoms total summary score of the 4 global domain scores (ranging from 0 to 20, higher scores indicating more positive symptoms).^eAs assessed with the Scale for the Assessment of Negative Symptoms total summary score of the 5 global domain scores (ranging from 0 to 25, higher scores indicating more negative symptoms).^fAs assessed with the Calgary Depression Scale total score (ranging from 0–27, higher scores indicating more depressive symptoms).^gAs assessed with the Brief Symptom Inventory Anxiety Scale total score (ranging from 0–24, higher scores indicating more anxiety symptoms).^hAs assessed with the 10-item Connor-Davidson Resilience Scale (ranging from 0–40, higher scores indicating greater overall resilience).ⁱAs assessed with the Short Form Health Survey (SF-36) Mental Composite score (computable range from -1.3 to 62.1, higher scores indicating better mental health).^jAs assessed with the Perceived Stress Scale (ranging from 0–40, higher scores indicating greater perceived stress).^kAs assessed with the Modified Telephone Interview for Cognitive Status (TICS-M) (ranging from 0–50, higher scores indicating better cognitive status).^lAs assessed with the Delis-Kaplan Executive Function System (reported as a standardized *z*-score, with higher values indicating better executive functioning).^mAs assessed with the Short Form Health Survey (SF-36) Physical Composite score (computable range from 1.7–76.3 from 0–100, higher scores indicating better physical health).ⁿAs assessed with the Cumulative Illness Rating Scale total score (ranging from 0–56, higher scores indicating a higher number or greater severity of physical comorbidities).^oAs assessed with the Childhood Trauma Questionnaire (CTQ). Subscale scores range from 5–25 (higher scores indicating greater childhood adversity).Abbreviations: hemoglobin A_{1c} = glycosylated hemoglobin, HOMA-IR = homeostatic model assessment for insulin resistance.

physical health measures between subgroups with varying trauma severity and resilience levels. Resilience levels were described by tertiles, similar to several published studies on resilience and trauma.^{34–36}

Statistical significance was defined as $P < .05$ (2-tailed). In addition, we calculated the effect sizes and interpreted those with medium or larger effect sizes (ie, Cohen $d \geq 0.5$ or $r \geq 0.30$) as clinically meaningful.

RESULTS

Comparison of NC and Schizophrenia Group Means and Proportions

The schizophrenia and NC groups were comparable on age, gender, and race/ethnicity (Table 1). The schizophrenia group had less education, more depression, worse self-reported mental well-being, worse cognition, worse physical

It is illegal to post this copyrighted PDF on any website.

Table 2. Spearman Correlations Between Trauma Severity and Key Sociodemographic, Mental, and Physical Health Variables in Study Participants With and Without Schizophrenia^a

	Nonpsychiatric Participants, Total CTQ Score			Schizophrenia Group, Total CTQ Score			Test for Equal Correlations	
	r	P	n	r	P	n	z	P
Sociodemographic								
Age at visit	0.07	.48	99	−0.04	.68	114	0.79	.21
Education (y)	−0.19	.06	99	−0.10	.29	114	−0.63	.27
Psychopathology								
Duration of illness				0.13	.18	111		
Antipsychotic dose, mg ^b				−0.08	.41	114		
Positive symptoms ^c				0.13	.17	114		
Negative symptoms ^d				0.02	.87	114		
Depressive symptoms ^e	0.34	.001	98	0.02	.8	114	2.35	.009
Anxiety symptoms ^f	0.20	.06	90	0.09	.35	111	0.80	.21
Mental health								
Resilience ^g	−0.07	.49	90	−0.20	.03	110	0.92	.18
Mental well-being ^h	−0.21	.05	90	−0.10	.3	111	−0.77	.22
Perceived stress ⁱ	0.21	.05	89	0.12	.21	111	0.64	.26
Overall cognitive dysfunction ^j	−0.15	.14	97	0.11	.28	111	−1.83	.03
Executive functioning ^k	−0.10	.35	99	−0.06	.53	114	−0.26	.40
Physical health								
Physical well-being ^l	−0.29	.005	90	−0.25	.008	111	−0.30	.38
Physical comorbidity ^m	0.26	.006	99	0.06	.52	114	1.57	.06
BMI	0.14	.16	99	0.29	.002	112	−1.08	.14
Biomarkers								
Fasting glucose, mg/dL	0.06	.53	99	0.09	.32	113	−0.22	.41
Fasting insulin, mIU/L	0.27	.009	95	0.23	.02	106	0.25	.40
Hemoglobin A _{1c} , %	0.13	.23	85	0.13	.21	95	0	.50
HOMA-IR	0.26	.01	95	0.23	.02	106	0.24	.40

^aBoldface indicates statistical significance.

^bAntipsychotic medication daily dosages were converted to WHO average daily doses based on published standards (WHO Guidelines for ATC Classification and DDD Assignment⁶⁶ and WHO Introduction to Drug Utilization Research⁶⁷).

^cAs assessed with the Scale for the Assessment of Positive Symptoms total summary score of the 4 global domain scores (ranging from 0–20, higher scores indicating more positive symptoms).

^dAs assessed with the Scale for the Assessment of Negative Symptoms total summary score of the 5 global domain scores (ranging from 0–25, higher scores indicating more negative symptoms).

^eAs assessed with the Calgary Depression Scale total score (ranging from 0–27, higher scores indicating more depressive symptoms).

^fAs assessed with the Brief Symptom Inventory Anxiety Scale total score (ranging from 0–24, higher scores indicating more anxiety symptoms).

^gAs assessed with the 10-item Connor-Davidson Resilience Scale (ranging from 0–40, higher scores indicating greater overall resilience).

^hAs assessed with the Short Form Health Survey (SF-36) Mental Composite score (computable range from −1.3 to 62.1, higher scores indicating better mental well-being).

ⁱAs assessed with the Perceived Stress Scale (ranging from 0–40, higher scores indicating greater perceived stress).

^jAs assessed with the Modified Telephone Interview for Cognitive Status (ranging from 0–50, higher scores indicating better cognitive status).

^kAs assessed with the Delis-Kaplan Executive Function System (reported as a standardized z-score, with higher values indicating better executive functioning).

^lAs assessed with the Short Form Health Survey (SF-36) Physical Composite score (ranging from 0–100, computable range from 1.7–76.3, with higher scores indicating better physical well-being).

^mAs assessed with the Cumulative Illness Rating Scale total score (ranging from 0–56, higher scores indicating a higher number or greater severity of physical comorbidities).

Abbreviations: BMI = body mass index, CTQ = Childhood Trauma Questionnaire, hemoglobin A_{1c} = glycosylated hemoglobin, HOMA-IR = homeostatic model assessment for insulin resistance.

well-being, higher BMI, and worse biomarkers of metabolic function (insulin, glucose, glycosylated hemoglobin, HOMA-IR). Additionally, the schizophrenia group had significantly higher rates of childhood trauma than NCs across all the CTQ subscales.

Bivariate Correlations of Childhood Trauma With Other Characteristics

The Spearman ρ correlations between severity of childhood adversity (CTQ total score) with sociodemographic, psychopathological, and mental

health variables differed significantly only on depressive symptoms and overall cognitive dysfunction between the NC and schizophrenia groups (Table 2). While CTQ total score was significantly correlated with depressive symptoms, worse mental well-being, and perceived stress in the NC group, such relationships were not seen in the schizophrenia group. In both groups, CTQ total scores were significantly associated with physical well-being, fasting insulin, and HOMA-IR. Correlations with physical health and biomarkers did not differ between the participant groups.


Comparison of Low, Moderate, and High Resilience Groups

Within the NC and schizophrenia groups, those in the high resilience tertile had better mental well-being, regardless of trauma severity, compared to those with moderate or low resilience (Figure 1A). Significant differences in mental well-being were observed between the lowest and highest resilience tertiles in the NC group and between all tertiles in the schizophrenia group. Results of a general linear model showed that resilience and subject group contributed significantly to mental well-being ($R^2 = 0.45$; Table 3). The schizophrenia subgroup with high resilience and severe trauma had mental well-being scores that were comparable to or better than those of NCs with low resilience and severe trauma ($t_{28} = 0.28$, $P = .8$, $d = 0.1$).


Similarly, high resilience was associated with improved physical well-being and metabolic biomarkers, including glycosylated hemoglobin (Figure 1B). While significant differences in glycosylated hemoglobin levels were noted between the lowest and other resilience tertiles in the NC group ($P = .001$ and $P = .008$), no significant differences were seen among the schizophrenia subgroups ($P > .10$). The general linear models showed that resilience contributed significantly to the outcomes of physical well-being ($R^2 = 0.25$), glycosylated hemoglobin ($R^2 = 0.10$), and HOMA-IR ($R^2 = 0.20$), but not BMI. Of note is that, unlike with mental well-being, subject group did not have a significant main effect on the physical health outcomes, which may reflect the importance of trauma history and resilience on physical health, regardless of serious mental illness. Persons with schizophrenia who had high resilience and

Figure 1. Resilience and Mental Well-Being Scores and Glycosylated Hemoglobin in Participants With and Without Schizophrenia^a

A. Mental Well-Being



B. Glycosylated Hemoglobin



^a**High resilience tertile:** nonpsychiatric subjects with low trauma (CDRS score > 36.7), nonpsychiatric subjects with severe trauma (CDRS score > 36.0), schizophrenia subjects with low trauma (CDRS score > 30.0), schizophrenia subjects with severe trauma (CDRS score > 27.0).

Moderate resilience tertile: nonpsychiatric subjects with low trauma (CDRS score between 31.3 and 36.7), nonpsychiatric subjects with severe trauma (CDRS score between 31.0 and 36.0), schizophrenia subjects with low trauma (CDRS score between 21.0 and 30.0), schizophrenia subjects with severe trauma (CDRS score between 18.0 and 27.0).

Low resilience tertile: nonpsychiatric subjects with low trauma (CDRS score < 31.3), nonpsychiatric subjects with severe trauma (CDRS score < 31.0), schizophrenia subjects with low trauma (CDRS score < 21.0), schizophrenia subjects with severe trauma (CDRS score < 18.0).

Abbreviations: CDRS = Connor-Davidson Resilience Scale, hemoglobin A_{1c} = glycosylated hemoglobin, SF-36 = Short Form Health Survey.

severe trauma had comparable or better physical health as NCs with low resilience and severe trauma across a number of measures: physical well-being ($t_{28} = 0.11$, $P = .91$, $d = 0.04$), glycosylated hemoglobin ($t_{28} = 1.07$, $P = .29$, $d = 0.42$), and HOMA-IR ($t_{27} = 0.77$, $P = .45$, $d = 0.32$).

DISCUSSION

Consistent with our a priori hypotheses, relative to NCs, people with schizophrenia reported significantly more childhood emotional abuse/neglect, physical abuse/neglect, and sexual abuse. In the NC group, such childhood trauma

was associated with worse mental and physical health; however, in the schizophrenia group, childhood adversity was associated with worse physical, but not mental, health. Resilience was associated with significantly better mental and physical health outcomes and metabolic biomarkers, regardless of trauma severity.

Overall, the higher prevalence and severity of childhood trauma among persons with schizophrenia compared to NCs were consistent with the literature.^{6–8} The values of CTQ total and subscale scores in our study were comparable to those reported in investigations of schizophrenia and NC groups.^{14,62,63}

Table 3. General Linear Models Examining the Relationships of Subject Group, Trauma Severity, and Resilience^a

Outcome	Model 1 ^b				Model 2 ^c			
	Main Effects and Interactions	Parameter Estimates (SE)	P Value	Cohen <i>d</i>	Main Effects and Interactions	Parameter Estimates (SE)	P Value	Cohen <i>d</i>
Mental well-being	Subject group	12.7 (4.0)	.002	0.47	Subject group	16.7 (6.9)	.017	0.35
	Trauma severity	−0.037 (0.052)	.18	0.19	Trauma severity	0.035 (0.046)	.69	0.06
	Group × severity	−0.045 (0.088)	.61	0.07	Resilience	0.70 (0.097)	<.001	1
					Group × severity	−0.1 (0.08)	.2	0.19
Physical well-being	Subject group	5.2 (4.1)	.21	0.18	Group × resilience	−0.23 (0.18)	.2	0.19
	Trauma severity	−0.16 (0.05)	.002	0.46	Subject group	−2.2 (8.0)	.08	0.04
	Group × severity	0.028 (0.092)	.76	0.04	Trauma severity	−0.13 (0.05)	.008	0.39
					Resilience	0.31 (0.11)	<.001	0.55
BMI	Subject group	−1.7 (2.8)	.54	0.09	Group × severity	0.016 (0.09)	.86	0.03
	Trauma severity	0.089 (0.038)	.07	0.25	Group × resilience	0.15 (0.21)	.46	0.11
	Group × severity	−0.067 (0.062)	.28	0.15	Subject group	7.4 (5.8)	.2	0.19
					Trauma severity	0.095 (0.039)	.12	0.23
Hemoglobin A _{1c}	Subject group	−0.019 (0.027)	.49	0.11	Resilience	0.032 (0.081)	.21	0.18
	Trauma severity	<0.001 (<0.001)	.56	0.08	Group × severity	−0.09 (0.07)	.17	0.2
	Group × severity	−4.8E-5 (0.001)	.94	0.01	Group × resilience	−0.25 (0.15)	.1	0.24
					Subject group	0.06 (0.05)	.24	0.19
HOMA-IR	Subject group	−0.26 (0.16)	.1	0.24	Trauma severity	<0.001 (<0.001)	1	0.007
	Trauma severity	0.005 (0.002)	.002	0.45	Resilience	−0.001 (0.001)	.002	0.5
	Group × severity	0.001 (0.004)	.77	0.04	Group × severity	<0.001 (0.001)	.76	<0.09
					Group × resilience	−0.002 (0.001)	.15	0.23
					Subject group	−0.15 (0.32)	.64	0.07
					Trauma severity	0.003 (0.002)	.009	0.4
					Resilience	−0.01 (0.005)	.01	0.39
					Group × severity	0.003 (0.004)	.45	0.11
					Group × resilience	−0.003 (0.008)	.74	0.05

^aBoldface indicates statistical significance.^bModel 1: subject group, trauma severity, subject group × trauma severity.^cModel 2: subject group, trauma severity, resilience, subject group × trauma severity, subject group × resilience.Abbreviations: BMI = body mass index, hemoglobin A_{1c} = glycosylated hemoglobin, HOMA-IR = homeostatic model assessment for insulin resistance.

In contrast to some published studies,^{11,14} trauma was not consistently associated with worse psychopathology or mental health across a variety of measures in the schizophrenia group. The lack of a significant association between childhood trauma and worse mental well-being in the schizophrenia group could be related to a longer average duration of illness in our participants relative to the Andrianarisoa et al¹⁴ and van Dam et al¹¹ samples. Illness-related stigma and other stresses over a long period of time may contribute to current psychopathology and mental health, independently of childhood adversity. Other differences include the van Dam et al¹¹ sample's inclusion of inpatients and the use of different scales to assess psychopathology and quality of life, thus making direct comparisons not possible. It may be noted, however, that in retrospect the lack of such an association in the context of schizophrenia is not counterintuitive. People with schizophrenia have a neurodevelopmental disorder that strongly influences the expression of psychopathologic symptoms. Moreover, there is substantial heterogeneity among people with schizophrenia in terms of the severity and pattern of brain-based impairment. In that context, the negative effects of childhood trauma on psychopathology may be less salient in people with schizophrenia, given the many other competing factors (eg, genetic factors, medication adherence).

Our study has several limitations. The cross-sectional design of our study limits the ability to make causal inferences

between clinical variables, including resilience, assessed in the present with retrospective reports of childhood adversity. In this sample with an average age of 48 years, the childhood adversity may have occurred many years ago. Despite the absence of a significant effect of childhood adversity found in this study, childhood adversity has been consistently shown to have important effects on symptoms and functioning in persons with psychotic disorders and the general public. A prospective study is needed to assess whether resilience mitigates the damaging effects of childhood adversity. A recent review found no clear “gold standard” among the 14+ resilience scales.⁶⁷ Self-reported CDRS scores may be subject to social desirability bias among the participants. There may be drawbacks of the CTQ compared to clinical interviews or longer scales such as the Life Experiences Questionnaire that might collect more detailed information about the trauma history. This study used the CTQ as it was well validated, well studied, and easy to administer and correlated well with qualitative interview and corroborative data sources (ie, interviews with family and other informants, child welfare records).^{61,68}

Strengths of our study include a relatively large sample size of over 100 participants with schizophrenia and over 100 NCs, comprehensive and well-validated assessments of mental and physical health, and inclusion of clinically relevant biomarkers. Despite its limitations, the CDRS is easy and efficient to administer, is well studied in the literature, and has the best psychometric ratings.⁶⁷

These current findings suggest that resilience has an important role in mental and metabolic health in people with schizophrenia and NCs. While individuals diagnosed with schizophrenia report higher prevalence of childhood trauma and have generally worse mental and physical health, including metabolic biomarkers, resilience is a potentially modifiable protective factor that could bolster mental and physical health. Along similar lines, our previous work on successful aging in a large community-dwelling cohort of NCs aged 50 to 99 years (N = 1,006) reported a strong association between resilience and successful aging that was comparable to the relationship between the absence of physical disability and successful aging.⁶⁹ In fact, high levels of resilience seemed to enable persons with schizophrenia and severe trauma to have comparable or better mental and physical health outcomes as NCs with severe trauma and low levels of resilience. This finding suggests a promising opportunity to improve functioning in persons with schizophrenia as well as NCs with a history of childhood trauma.

Resilience-enhancing interventions exist across a variety of settings, including military training^{70,71} as well

as Stress Management and Resilience Training (SMART)⁷² and Mindfulness-Based Stress Reduction.^{73,74} However, aside from 1 pilot study of positive psychotherapy⁷⁵ and individual resiliency training (eg, using positive psychology exercise to improve self-esteem and self-efficacy for illness management) for persons with first-episode psychosis,⁷⁶ specific resilience-focused interventions have not been tested in persons with schizophrenia, and, furthermore, the metabolic effects of such interventions have not been assessed. The latter is particularly important in the context of schizophrenia because of the high prevalence of metabolic disorders in schizophrenia, the association of the latter to early mortality, and tentative correlational findings suggestive that resilience may decrease the risk of metabolic disorders. Although causal relationships cannot be determined here, the potential benefits and relative low risk/cost of resilience interventions suggest strong reasons for prospective studies testing such interventions among people with schizophrenia (with or without a history of childhood trauma) on physical health outcomes, especially metabolic effects.^{1,2}

Submitted: June 30, 2017; accepted January 8, 2018.

Published online: April 17, 2018.

Author contributions: Dr Lee conducted literature reviews, data analyses, data interpretation, and manuscript preparation. Dr Martin was involved in data collection and manuscript preparation. Dr Tu was involved in data analyses and statistical modeling, data interpretation, and manuscript preparation. Dr Palmer was involved in data interpretation and manuscript preparation. Dr Jeste designed the study, obtained funding to support this work, and was involved in data interpretation and manuscript preparation.

Potential conflicts of interest: The authors declare no financial or other relationship relevant to the subject of this article.

Funding/support: This study was supported, in part, by National Institutes of Health (R01MH094151-01 [principal investigator (PI): Dr Jeste]), the National Institute of Mental Health (T32 Geriatric Mental Health Program MH019934 [PI: Dr Jeste]), and the Stein Institute for Research on Aging at the University of California, San Diego.

Role of the sponsor: The funding organizations had no role in study design, data collection and analysis, decision to submit, or preparation of the manuscript.

Acknowledgments: The authors thank all of the study participants and staff. The authors also thank Rebecca Daly, AA (Department of Psychiatry and Sam and Rose Stein Institute for Research on Aging, University of California San Diego, La Jolla, California) for support with data management and analyses. Ms Daly has no conflicts of interest to declare.

Previous presentation: Presented at the Symposium on Childhood Adversity; University of California, San Diego; May 17, 2017.

REFERENCES

- Brewer-Smyth K, Cornelius M, Pohlig RT. Childhood adversity and mental health correlates of obesity in a population at risk. *J Correct Health Care*. 2016;22(4):367–382.
- Joung KE, Park KH, Zaichenko L, et al. Early life adversity is associated with elevated levels of circulating leptin, irisin, and decreased levels of adiponectin in midlife adults. *J Clin Endocrinol Metab*. 2014;99(6):E1055–E1060.
- Brown DW, Anda RF, Tiemeier H, et al. Adverse childhood experiences and the risk of premature mortality. *Am J Prev Med*. 2009;37(5):389–396.
- Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the Adverse Childhood Experiences (ACE) Study. *Am J Prev Med*. 1998;14(4):245–258.
- Afifi TO, MacMillan HL, Boyle M, et al. Child abuse and physical health in adulthood. *Health Rep*. 2016;27(3):10–18.
- Bendall S, Jackson HJ, Hulbert CA, et al. Childhood trauma and psychotic disorders: a systematic, critical review of the evidence. *Schizophr Bull*. 2008;34(3):568–579.
- Trotta A, Murray RM, Fisher HL. The impact of childhood adversity on the persistence of psychotic symptoms: a systematic review and meta-analysis. *Psychol Med*. 2015;45(12):2481–2498.
- Morgan C, Fisher H. Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma—a critical review. *Schizophr Bull*. 2007;33(1):3–10.
- van Nierop M, Janssens M, Bruggeman R; Genetic Risk Outcome of Psychosis Investigators. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. *PLoS One*. 2013;8(11):e76690.
- Larsson S, Andreassen OA, Aas M, et al. High prevalence of childhood trauma in patients with schizophrenia spectrum and affective disorder. *Compr Psychiatry*. 2013;54(2):123–127.
- van Dam DS, van Nierop M, Viechtbauer W, et al. Childhood abuse and neglect in relation to the presence and persistence of psychotic and depressive symptomatology. *Psychol Med*. 2015;45(7):1363–1377.
- Gil A, Gama CS, de Jesus DR, et al. The association of child abuse and neglect with adult disability in schizophrenia and the prominent role of physical neglect. *Child Abuse Negl*. 2009;33(9):618–624.
- Hassan AN, De Luca V. The effect of lifetime adversities on resistance to antipsychotic treatment in schizophrenia patients. *Schizophr Res*. 2015;161(2-3):496–500.
- Andrianarisoa M, Boyer L, Godin O, et al. Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia: results from the national FACE-SZ cohort. *Schizophr Res*. 2017;185:173–181.
- Gallagher BJ 3rd, Jones BJ. Childhood stressors and symptoms of schizophrenia. *Clin Schizophr Relat Psychoses*. 2013;7(3):124–130.
- Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. *Am Heart J*. 2005;150(6):1115–1121.
- Jeste DV, Wolkowitz OM, Palmer BW. Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. *Schizophr Bull*. 2011;37(3):451–455.
- Stubbs B, Vancampfort D, De Hert M, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. *Acta Psychiatr Scand*. 2015;132(2):144–157.
- Sorensen HJ, Nielsen PR, Benros ME, et al. Somatic diseases and conditions before the first diagnosis of schizophrenia: a nationwide population-based cohort study in more than 900,000 individuals. *Schizophr Bull*. 2015;41(2):513–521.
- Pillinger T, Beck K, Gobjila C, et al. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. *JAMA Psychiatry*. 2017;74(3):261–269.
- Song X, Fan X, Song X, et al. Elevated levels of adiponectin and other cytokines in drug naive, first episode schizophrenia patients with normal weight. *Schizophr Res*. 2013;150(1):269–273.
- Kirkpatrick B, Messias E, Harvey PD, et al. Is schizophrenia a syndrome of accelerated aging? *Schizophr Bull*. 2008;34(6):1024–1032.
- Rajkumar RP. The impact of childhood adversity on the clinical features of

It is illegal to post this copyrighted PDF on any website.

- schizophrenia. *Schizophr Res Treatment*. 2015;532082.
24. Misiak B, Kiejna A, Frydecka D. The history of childhood trauma is associated with lipid disturbances and blood pressure in adult first-episode schizophrenia patients. *Gen Hosp Psychiatry*. 2015;37(4):365–367.
25. Hepgul N, Pariante CM, Dapasquale S, et al. Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients. *Psychol Med*. 2012;42(9):1893–1901.
26. Berens AE, Jensen SKG, Nelson CA 3rd. Biological embedding of childhood adversity: from physiological mechanisms to clinical implications. *BMC Med*. 2017;15(1):135.
27. Lavretsky H. *Resilience and Aging: Research and Practice*. Baltimore, MD: Johns Hopkins University Press; 2014.
28. Rana BK, Darst BF, Bloss C, et al. Candidate SNP associations of optimism and resilience in older adults: exploratory study of 935 community-dwelling adults. *Am J Geriatr Psychiatry*. 2014;22(10):997–1006.e5.
29. Martin AS, Distelberg B, Palmer BW, et al. Development of a new multidimensional individual and interpersonal resilience measure for older adults. *Aging Ment Health*. 2015;19(1):32–45.
30. Herrman H, Stewart DE, Diaz-Granados N, et al. What is resilience? *Can J Psychiatry*. 2011;56(5):258–265.
31. Amstadter AB, Myers JM, Kendler KS. Psychiatric resilience: longitudinal twin study. *Br J Psychiatry*. 2014;205(4):275–280.
32. Lamond AJ, Depp CA, Allison M, et al. Measurement and predictors of resilience among community-dwelling older women. *J Psychiatr Res*. 2008;43(2):148–154.
33. Yi JP, Vitaliano PP, Smith RE, et al. The role of resilience on psychological adjustment and physical health in patients with diabetes. *Br J Health Psychol*. 2008;13(pt 2):311–325.
34. Wingo AP, Briscione M, Norrholm SD, et al. Psychological resilience is associated with more intact social functioning in veterans with post-traumatic stress disorder and depression. *Psychiatry Res*. 2017;249:206–211.
35. Wingo AP, Ressler KJ, Bradley B. Resilience characteristics mitigate tendency for harmful alcohol and illicit drug use in adults with a history of childhood abuse: a cross-sectional study of 2024 inner-city men and women. *J Psychiatr Res*. 2014;51:93–99.
36. Poole JC, Dobson KS, Pusch D. Childhood adversity and adult depression: The protective role of psychological resilience. *Child Abuse Negl*. 2017;64:89–100.
37. Chan CL, Chan TH, Ng SM. The Strength-Focused and Meaning-Oriented Approach to Resilience and Transformation (SMART): a body-mind-spirit approach to trauma management. *Soc Work Health Care*. 2006;43(2–3):9–36.
38. Shen K, Zeng Y. The association between resilience and survival among Chinese elderly. In: Resnick B, Roberto K, Gwyther L, eds. *Handbook of Resilience in Aging: The Key to Successful Aging*. 4th ed. New York, NY: Springer; 2010.
39. Brix C, Schleussner C, Fuller J, et al. The need for psychosocial support and its determinants in a sample of patients undergoing radiooncological treatment of cancer. *J Psychosom Res*. 2008;65(6):541–548.
40. Gotay CC, Isaacs P, Pagano I. Quality of life in patients who survive a dire prognosis compared to control cancer survivors. *Psychooncology*. 2004;13(12):882–892.
41. Joseph J, Depp C, Martin AS, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. *Schizophr Res*. 2015;168(1–2):456–460.
42. Wolkowitz OM, Jeste DV, Martin AS, et al. Leukocyte telomere length: effects of schizophrenia, age, and gender. *J Psychiatr Res*. 2017;85:42–48.
43. Lee EE, Hong S, Martin AS, et al. Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables. *Am J Geriatr Psychiatry*. 2017;25(1):50–61.
44. Lee EE, Eyler LT, Wolkowitz OM, et al. Elevated plasma F2-isoprostane levels in schizophrenia. *Schizophr Res*. 2016;176(2–3):320–326.
45. Hong S, Lee EE, Martin AS, et al. Abnormalities in chemokine levels in schizophrenia and their clinical correlates. *Schizophr Res*. 2017;181:63–69.
46. Edmonds EC, Martin AS, Palmer BW, et al. Positive mental health in schizophrenia and healthy comparison groups: relationships with overall health and biomarkers. *Aging Ment Health*. 2018;22(3):354–362.
47. First M, Spitzer RL, Gibbon M, Williams JBW. *Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P)*. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
48. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59(suppl 20):22–33, quiz 34–57.
49. Andreasen NC, Olsen S. Negative v positive schizophrenia: definition and validation. *Arch Gen Psychiatry*. 1982;39(7):789–794.
50. Andreasen NC, Arndt S, Alliger R, et al. Symptoms of schizophrenia: methods, meanings, and mechanisms. *Arch Gen Psychiatry*. 1995;52(5):341–351.
51. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. *Schizophr Res*. 1990;3(4):247–251.
52. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. *Psychol Med*. 1983;13(3):595–605.
53. Campbell-Sills L, Stein MB. Psychometric analysis and refinement of the Connor-Davidson Resilience Scale (CD-RISC): validation of a 10-item measure of resilience. *J Trauma Stress*. 2007;20(6):1019–1028.
54. Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). *Depress Anxiety*. 2003;18(2):76–82.
55. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I: conceptual framework and item selection. *Med Care*. 1992;30(6):473–483.
56. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav*. 1983;24(4):385–396.
57. van den Berg E, Ruis C, Biessels GJ, et al. The Telephone Interview for Cognitive Status (Modified): relation with a comprehensive neuropsychological assessment. *J Clin Exp Neuropsychol*. 2012;34(6):598–605.
58. Welsh KA, Breitner JC, Magruder-Habib KM. Detection of dementia in the elderly using telephone screening of cognitive status. *Neuropsychiatry Neuropsychol Behav Neurol*. 1993;6(2):103–110.
59. Delis D, Kaplan E, Kramer J. *Delis-Kaplan Executive Function Scale (D-KEFS): Examiner's Manual*. San Antonio, TX: The Psychological Corporation; 2001.
60. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. *J Am Geriatr Soc*. 1968;16(5):622–626.
61. Bernstein DP, Fink L, Handelsman L, et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. *Am J Psychiatry*. 1994;151(8):1132–1136.
62. Schafer I, Harfst T, Aderhold V, et al. Childhood trauma and dissociation in female patients with schizophrenia spectrum disorders: an exploratory study. *J Nerv Ment Dis*. 2006;194(2):135–138.
63. Kingdon DG, Ashcroft K, Bhandari B, et al. Schizophrenia and borderline personality disorder: similarities and differences in the experience of auditory hallucinations, paranoia, and childhood trauma. *J Nerv Ment Dis*. 2010;198(6):399–403.
64. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28(7):412–419.
65. World Health Organization. *Guidelines for ATC Classification and DDD Assignment*. 13th ed. Oslo, Norway: WHO; 2010.
66. World Health Organization. *Introduction to Drug Utilization Research*. Oslo, Norway: WHO; 2009.
67. Windle G, Bennett KM, Noyes J. A methodological review of resilience measurement scales. *Health Qual Life Outcomes*. 2011;9(1):8.
68. Bernstein DP, Stein JA, Newcomb MD, et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. *Child Abuse Negl*. 2003;27(2):169–190.
69. Jeste DV, Savla GN, Thompson WK, et al. Association between older age and more successful aging: critical role of resilience and depression. *Am J Psychiatry*. 2013;170(2):188–196.
70. Adler AB, Williams J, McGurk D, et al. Resilience training with soldiers during basic combat training: randomisation by platoon. *Appl Psychol Health Well-Being*. 2015;7(1):85–107.
71. Saltzman WR, Lester P, Beardslee WR, et al. Mechanisms of risk and resilience in military families: theoretical and empirical basis of a family-focused resilience enhancement program. *Clin Child Fam Psychol Rev*. 2011;14(3):213–230.
72. Loprinzi CE, Prasad K, Schroeder DR, et al. Stress Management and Resilience Training (SMART) program to decrease stress and enhance resilience among breast cancer survivors: a pilot randomized clinical trial. *Clin Breast Cancer*. 2011;11(6):364–368.
73. Rose RD, Buckley JC Jr, Zbozinek TD, et al. A randomized controlled trial of a self-guided, multimedia, stress management and resilience training program. *Behav Res Ther*. 2013;51(2):106–112.
74. Creswell JD, Irwin MR, Burklund LJ, et al. Mindfulness-Based Stress Reduction training reduces loneliness and pro-inflammatory gene expression in older adults: a small randomized controlled trial. *Brain Behav Immun*. 2012;26(7):1095–1101.
75. Meyer PS, Johnson DP, Parks A, et al. Positive living: a pilot study of group positive psychotherapy for people with schizophrenia. *J Posit Psychol*. 2012;7(3):239–248.
76. Mueser KT, Penn DL, Addington J, et al. The NAVIGATE program for first-episode psychosis: rationale, overview, and description of psychosocial components. *Psychiatr Serv*. 2015;66(7):680–690.

You are prohibited from making this PDF publicly available.